KNIGHT THERAPEUTICS INC (GUD.CA) Stock Fundamental Analysis
TSX:GUD - Toronto Stock Exchange - CA4990531069 - Common Stock - Currency: CAD
GUD gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 33 industry peers in the Pharmaceuticals industry. The financial health of GUD is average, but there are quite some concerns on its profitability. GUD is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year GUD was profitable.
GUD had a positive operating cash flow in the past year.
In multiple years GUD reported negative net income over the last 5 years.
GUD had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of GUD (1.10%) is better than 78.79% of its industry peers.
GUD has a better Return On Equity (1.39%) than 75.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.1% | ||
| ROE | 1.39% | ||
| ROIC | N/A |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GUD has a Profit Margin of 2.97%. This is in the better half of the industry: GUD outperforms 78.79% of its industry peers.
In the last couple of years the Profit Margin of GUD has declined.
GUD's Gross Margin of 44.95% is fine compared to the rest of the industry. GUD outperforms 60.61% of its industry peers.
In the last couple of years the Gross Margin of GUD has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 2.97% | ||
| GM | 44.95% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
GUD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GUD has been reduced compared to 1 year ago.
The number of shares outstanding for GUD has been reduced compared to 5 years ago.
The debt/assets ratio for GUD has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.61 indicates that GUD is not a great score, but indicates only limited risk for bankruptcy at the moment.
With an excellent Altman-Z score value of 2.61, GUD belongs to the best of the industry, outperforming 84.85% of the companies in the same industry.
A Debt/Equity ratio of 0.04 indicates that GUD is not too dependend on debt financing.
The Debt to Equity ratio of GUD (0.04) is better than 72.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.61 |
ROIC/WACCN/A
WACC8.93%
2.3 Liquidity
A Current Ratio of 2.97 indicates that GUD has no problem at all paying its short term obligations.
GUD's Current ratio of 2.97 is fine compared to the rest of the industry. GUD outperforms 75.76% of its industry peers.
A Quick Ratio of 2.06 indicates that GUD has no problem at all paying its short term obligations.
GUD has a Quick ratio of 2.06. This is in the better half of the industry: GUD outperforms 78.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.97 | ||
| Quick Ratio | 2.06 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 131.25% over the past year.
The earnings per share for GUD have been decreasing by -13.46% on average. This is quite bad
The Revenue has grown by 12.21% in the past year. This is quite good.
The Revenue has been growing by 50.87% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)131.25%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%148.55%
Revenue 1Y (TTM)12.21%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%2.66%
3.2 Future
GUD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.52% yearly.
GUD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.78% yearly.
EPS Next Y13.52%
EPS Next 2Y29.64%
EPS Next 3Y17.35%
EPS Next 5Y44.52%
Revenue Next Year9.9%
Revenue Next 2Y10.12%
Revenue Next 3Y7.13%
Revenue Next 5Y7.78%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 116.00, the valuation of GUD can be described as expensive.
GUD's Price/Earnings ratio is a bit cheaper when compared to the industry. GUD is cheaper than 69.70% of the companies in the same industry.
GUD is valuated expensively when we compare the Price/Earnings ratio to 26.70, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 69.02, GUD can be considered very expensive at the moment.
GUD's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. GUD is cheaper than 72.73% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.49, GUD is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 116 | ||
| Fwd PE | 69.02 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, GUD is valued a bit cheaper than 75.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 8.59 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
GUD's earnings are expected to grow with 17.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)8.58
PEG (5Y)N/A
EPS Next 2Y29.64%
EPS Next 3Y17.35%
5. Dividend
5.1 Amount
No dividends for GUD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:GUD (5/16/2025, 7:00:00 PM)
5.8
-0.04 (-0.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners11.48%
Inst Owner ChangeN/A
Ins Owners1.55%
Ins Owner ChangeN/A
Market Cap576.81M
Analysts76.36
Price Target7.71 (32.93%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.98%
Min Revenue beat(2)0.88%
Max Revenue beat(2)9.08%
Revenue beat(4)4
Avg Revenue beat(4)4.99%
Min Revenue beat(4)0.88%
Max Revenue beat(4)9.08%
Revenue beat(8)7
Avg Revenue beat(8)4.9%
Revenue beat(12)11
Avg Revenue beat(12)9.21%
Revenue beat(16)14
Avg Revenue beat(16)10.57%
PT rev (1m)0%
PT rev (3m)6.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-37.18%
EPS NY rev (1m)0%
EPS NY rev (3m)-31.46%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)9.39%
Revenue NY rev (1m)10.47%
Revenue NY rev (3m)10.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 116 | ||
| Fwd PE | 69.02 | ||
| P/S | 1.55 | ||
| P/FCF | N/A | ||
| P/OCF | 63.6 | ||
| P/B | 0.73 | ||
| P/tB | 1.33 | ||
| EV/EBITDA | 8.59 |
EPS(TTM)0.05
EY0.86%
EPS(NY)0.08
Fwd EY1.45%
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)0.09
OCFY1.57%
SpS3.75
BVpS8
TBVpS4.35
PEG (NY)8.58
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.1% | ||
| ROE | 1.39% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 2.97% | ||
| GM | 44.95% | ||
| FCFM | N/A |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
F-Score6
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.6 | ||
| Cap/Depr | 46.41% | ||
| Cap/Sales | 6.49% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 18.42% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.97 | ||
| Quick Ratio | 2.06 | ||
| Altman-Z | 2.61 |
F-Score6
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)40.08%
Cap/Depr(5y)130.51%
Cap/Sales(3y)6.77%
Cap/Sales(5y)24.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)131.25%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%148.55%
EPS Next Y13.52%
EPS Next 2Y29.64%
EPS Next 3Y17.35%
EPS Next 5Y44.52%
Revenue 1Y (TTM)12.21%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%2.66%
Revenue Next Year9.9%
Revenue Next 2Y10.12%
Revenue Next 3Y7.13%
Revenue Next 5Y7.78%
EBIT growth 1Y-220.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year371.68%
EBIT Next 3Y71.89%
EBIT Next 5Y49.76%
FCF growth 1Y-653.06%
FCF growth 3YN/A
FCF growth 5Y23.85%
OCF growth 1Y-71.04%
OCF growth 3Y-6.66%
OCF growth 5Y51.14%